Amgen has reported positive top-line data from the Phase III DAHLIA clinical trial of ABP 959 in adults with paroxysmal nocturnal hemoglobinuria (PNH).

ABP 959 is an investigational biosimilar candidate to Soliris (eculizumab).

The double-blind, randomised, active-controlled, two-period crossover trial analysed the safety and efficacy of ABP 959 versus Soliris in adult PNH patients, who priorly received eculizumab for a minimum of six months.

Trial subjects were categorised into a 1:1 ratio to receive each investigational product (IP) in one of two sequences over two periods, with a crossover.

According to the findings, the trial met the primary endpoints.

No clinically meaningful variations between ABP 959 and Soliris were reported at week 27, based on intravascular haemolysis control as assessed by lactate dehydrogenase (LDH).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the time-adjusted area under the effect curve (AUEC) of LDH, no clinically meaningful differences from week 13 to 27, from week 39 to 53, and from week 65 to 79 for the crossover comparison were observed.

In the trial, ABP 959’s safety and immunogenicity profiles were in line with Soliris.

A monoclonal antibody, ABP 959 attaches to the complement protein C5 and hinders classical and alternative complement cascade progression.

Amgen Research and Development executive vice-president David Reese said: “The positive results with ABP 959 demonstrate similar efficacy, safety and immunogenicity as the reference product, further highlighting Amgen’s commitment to providing patients with access to high-quality, biologic therapies.

“We look forward to working with regulators to make this potential biosimilar option available to patients.”

The company’s portfolio has 11 biosimilars, of which five have obtained approval in the US, three are approved in the European Union, and three are in the Phase III development stage.

In April this year, the company reported that the Phase III trial of ABP 654 in adult patients with moderate to severe plaque psoriasis met the primary efficacy endpoint.